



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

BAQSIMI

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion/ Notification ¹ issued on	Commission Decision Issued ² / amended on	Product Information affected ³	Summary
N/0007	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	18/06/2021		Labelling	
PSUSA/10826 /202007	Periodic Safety Update EU Single assessment - glucagon (for centrally authorised product only)	11/02/2021	n/a		PRAC Recommendation - maintenance
IA/0006/G	This was an application for a group of variations.	02/02/2021	n/a		

¹ Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

² A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

³ SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).



B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure

B.II.c.2.a - Change in test procedure for an excipient - Minor changes to an approved test procedure

B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure

B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure

B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure

B.II.c.2.a - Change in test procedure for an excipient - Minor changes to an approved test procedure

B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure

B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure

B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure

B.II.c.2.a - Change in test procedure for an excipient - Minor changes to an approved test procedure

B.II.c.2.a - Change in test procedure for an excipient - Minor changes to an approved test procedure

B.II.c.2.a - Change in test procedure for an excipient - Minor changes to an approved test procedure

	B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS				
PSUSA/10826 /202001	Periodic Safety Update EU Single assessment - glucagon (for centrally authorised product only)	03/09/2020	n/a		PRAC Recommendation - maintenance
IAIN/0004	B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing	06/07/2020	n/a		
IA/0002	B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place	17/04/2020	n/a		